Techcyte and Aiosyn collaborate to integrate AI-powered slide QC and mitotic counting into the Fusion™ digital pathology platform
Orem, UT, and Nijmegen, Netherlands — March 20, 2025 — Techcyte, a leader in digital pathology and Aiosyn, a leading developer of AI-driven pathology algorithms, today announced a collaboration that brings Aisoyn’s AI algorithms to the Fusion digital pathology platform.
Ensuring the quality of digital slides is a critical yet tedious and labor-intensive process for pathology labs. Aiosyn QC, Aiosyn’s AI-based slide quality control (QC) algorithm detects and highlights common artifacts in H&E and IHC slides, helping laboratories present only high-quality images to pathologists. This streamlines pathology workflows, aiming to improve efficiency, and enhances the accuracy of AI-assisted diagnostics by eliminating compromised or suboptimal images before pathologist review.
“High-quality imaging and AI-driven analysis are essential for advancing digital pathology. By bringing our slide QC and mitotic figure counting algorithms to Fusion, we’re ensuring that pathologists not only work with optimal images, but also have access to advanced AI insights that support more confident decision-making.”Patrick de Boer, CEO of Aiosyn
Beyond slide QC, the collaboration also brings Aiosyn Mitosis Breast, Aiosyn’s IVDR-certified mitotic counting algorithm for breast cancer images into the Fusion platform. Techcyte’s Fusion Platform is uniquely designed to comprehensively integrate third-party AI solutions, ensuring that AI insights are seamlessly integrated into the clinical workflow.
“Fusion is designed to embed third-party AI directly into the pathology workflow, eliminating inefficiencies and ensuring that insights are accessible when and where pathologists need them,” said Ben Cahoon, CEO of Techcyte. “By integrating Aiosyn’s slide QC and mitotic counting algorithms, we’re enabling a more fluid, efficient workflow that reduces distractions and helps pathologists focus on making the right diagnosis.”
By combining Aiosyn’s advanced pathology algorithms and Techcyte’s Fusion digital pathology platform, this collaboration demonstrates the power of an open, standards-based, fully integrated AI-enabled digital pathology ecosystem.
About Techcyte
Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that aim to improve the efficiency and accuracy of diagnostic testing.
Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence.
We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified anatomic and clinical pathology platform to labs and clinics around the world.
Visit techcyte.com for more information.
Techcyte’s anatomic and clinical pathology platform is for Research Use Only in the United States.
About Aiosyn
Based in the Netherlands, Aiosyn develops precision pathology software for breast cancer and kidney disease, integrating its solutions into standard pathology workflows. Aiosyn has been built upon more than 20 years of research experience in the field of pathology and is rooted in pathology practice.
For full product details, including regulatory status, visit AiosynQC and Aiosyn Mitosis Breast.
SOURCE: Aiosyn
